BN80927 in Patients With Advanced Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Malignant Solid Tumour
Interventions
DRUG

BN80927

Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.

Trial Locations (3)

Unknown

Centre Paul Papin, Angers

Centre Eugene Marquis, Rennes

Centre Rene Huguenin, Saint-Cloud

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY